Investors - About

Section titled

Leadership Team

  • dianne Head shot

    Dianne Carmichael

    Executive Chair

    Ms. Carmichael has over 30 years of diverse executive management and board of director experience spanning from start-up and growth companies to multinationals.

    Dianne was Chairman & CEO of a publicly traded investment firm before shifting to healthcare to make a difference in the lives of those touched by profound illness. As President of Best Doctors Inc., she helped create a remote second opinion platform that connected patients with the top 2% of medical experts worldwide and which today, covers over 40 million international patients. Most recently she was President Payer Markets and Head of Corporate Strategy and M&A at McKesson, a Fortune 500 healthcare company. Prior to that, Dianne was President, UHN Solutions at UHN, Canada’s leading group of research hospitals, and Managing Director, MaRS Health Ventures and Innovation. Today, Ms. Carmichael continues to make a difference for patients by helping health-tech companies bring high impact innovations to scale globally through her company, Carmichael Worldwide Inc. Dianne formerly served as the Chief Advisor for the HealthTech division of the Council of Canadian Innovators, founded by Jim Balsillie, where they bring the voice of Canadian tech CEOs to government and policy makers.

    Dianne has served on numerous healthcare boards, including Holland Bloorview Kids Rehab Hospital, PatientsCanada, CAPCH, Centre for Regenerative Medicine, Mt. Sinai’s Personalized Medicine Institute & W.I.N. 

    She was awarded Canada’s Most Powerful Women by WXN, Canadian Women Transforming Health Care and University of Waterloo Alumni of the Year. She holds a B.A. from the University of Waterloo.

  • Joe

    Joseph Walewicz

    Chief Business Officer

    Mr. Joseph Walewicz was Executive Vice President, Business and Corporate Development of Clementia Pharmaceuticals, a NASDAQ-listed company, from 2017 to 2019 prior to Clementia’s acquisition by Ipsen Pharmaceuticals for US$1 billion in April of 2019. Mr. Walewicz has spent 25 years in biopharma, serving on the board and at the executive level of multiple publicly traded biopharma companies including Clementia Pharmaceuticals, MethylGene (now Mirati Therapeutics Inc.), Warnex Inc. and Paladin Labs, and as a top ranked equities analyst for major banks including CIBC, BMO, Lehman Brothers where he covered publicly traded North American biotechnology, pharmaceuticals, medtech and healthcare services companies. Mr. Walewicz holds a Master of Business Administration, Finance (McGill), as well as a Bachelor of Science, Biochemistry, and a Bachelor of Arts, Economics from Queen’s University. Mr. Walewicz is also a CFA (Chartered Financial Analyst) charterholder and a member of the Licensing Executives Society (LES).

  • Jeff-1

    Jeff Zygouras CPA, CA

    Chief Financial Officer

    Mr. Zygouras joined NeuPath as Corporate Controller in September 2019 and was promoted to Interim Chief Financial Officer in July 2021. Mr. Zygouras has more than 10 years of progressive finance experience including over 7 years with TSX-listed public companies in the health care industry. Prior to NeuPath, Mr. Zygouras served as the Finance Manager at Miravo Healthcare (TSX:MRV)(formerly Nuvo Pharmaceuticals) where he supported the Company through the transformational acquisition of Aralez Pharmaceuticals to become one of the premier specialty pharmaceutical companies in Canada. Prior to working in the healthcare industry, Mr. Zygouras was a member of Ernst & Young Toronto where he completed his designation gaining experience in a variety of industries. Mr. Zygouras is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.

  • Ben

    Ben Fagan

    Chief Technology Officer

    Ben joined NeuPath as Chief Technology Officer in August 2021.  He brings over 15 years of experience from the technology and capital markets industries.  While at TD Securities and BMO Capital Markets, Ben worked in progressively senior leadership positions where most recently he managed the design and implementation of complex financial technology systems for billion-dollar businesses within the derivatives trading group across North America, Europe and Asia.  Since leaving the capital markets industry, Ben has founded three technology companies as CTO, including KumoCare, which provides technology solutions for the healthcare industry.  Ben holds a Master of Science in Financial Engineering from the University of Michigan, and a Bachelor of Engineering from Ontario Tech University.

  • Elaine-1

    Elaine McCulloch

    Vice President Marketing

    Appointed Vice President of Marketing in April 2021, Elaine McCulloch is responsible for leading the brand, digital and B2B marketing strategies for NeuPath. Elaine brings over 20 years of experience in marketing, sales and brand management. Elaine has been privileged to oversee the marketing efforts for some of Canada’s leading brands. Prior to joining NeuPath in 2021, Elaine lead the brand and marketing efforts for prominent media brands at Bell Media, including iHeartRadio, CTV, MUCH Music and HBO Canada. Prior to joining Bell Media, she held various positions over a 10-year career at VIA Rail that included product and promotional marketing and business development. Elaine began her marketing career in London UK, working in international marketing and sales for a series of international trade shows. Elaine holds an Honors of Sociology degree from The University of Western Ontario.

  • bjorn

    Bjorn Thies

    Vice President People And Culture

    Bjorn Thies joined NeuPath as Vice President People and Culture in April 2021. In this role, Bjorn is responsible for leading the People and Culture function of the organization with a strong focus on employee engagement, company culture, and organizational effectiveness. Bjorn has over 18 years of international Human Resources and Learning & Development experience. Prior to joining NeuPath, Bjorn has held several leadership positions within luxury hospitality, and high-end retail, including a 17-year career at Four Seasons Hotels and Resorts with assignments in Germany, England, the US, and Canada.

     

  • Denise

    Denise Hill

    Vice President Western Canada

    Ms. Hill joined NeuPath with the acquisition of HealthPointe Medical Centres in February 2021. As Vice President for Western Canada, she is responsible for both operational oversight and for building the NeuPath/HealthPointe brand in Western Canada. Ms. Hill has years of experience leading health industry organizations and providing strategic leadership in the healthcare field. She is the former CEO of HealthPointe and prior to that was Executive Director of a large orthopedic clinic in Edmonton, The Edmonton Bone and Joint Centre. Ms. Hill also previously worked for the Alberta Medical Association and Workers’ Compensation Board in Alberta in the areas of executive consulting and senior leadership. Ms. Hill holds an MBA from Queen’s University and an under graduate degree from the University of Alberta, as well as a Certificate in Occupational Health and Safety.

Section titled

Board of Directors

  • Dianne Carmichael - Director (Chair)

    Ms. Carmichael has over 30 years of diverse executive management and board of director experience spanning from start-up and growth companies to multinationals.

    Dianne was Chairman & CEO of a publicly traded investment firm before shifting to healthcare to make a difference in the lives of those touched by profound illness. As President of Best Doctors Inc., she helped create a remote second opinion platform that connected patients with the top 2% of medical experts worldwide and which today, covers over 40 million international patients. Most recently she was President Payer Markets and Head of Corporate Strategy and M&A at McKesson, a Fortune 500 healthcare company. Prior to that, Dianne was President, UHN Solutions at UHN, Canada’s leading group of research hospitals, and Managing Director, MaRS Health Ventures and Innovation. Today, Ms. Carmichael continues to make a difference for patients by helping health-tech companies bring high impact innovations to scale globally through her company, Carmichael Worldwide Inc. Dianne formerly served as the Chief Advisor for the HealthTech division of the Council of Canadian Innovators, founded by Jim Balsillie, where they bring the voice of Canadian tech CEOs to government and policy makers.

    Dianne has served on numerous healthcare boards, including Holland Bloorview Kids Rehab Hospital, PatientsCanada, CAPCH, Centre for Regenerative Medicine, Mt. Sinai’s Personalized Medicine Institute & W.I.N.

    She was awarded Canada’s Most Powerful Women by WXN, Canadian Women Transforming Health Care and University of Waterloo Alumni of the Year. She holds a B.A. from the University of Waterloo.

  • Jolyon Burton - Director

    Mr. Burton is a co-founder of Bloom Burton & Co. and serves as the firm’s President and Head of Investment Banking. As trusted advisors to boards of directors, management teams, and professional and strategic investors, Jolyon and his team help structure and execute financial and capital markets strategies, mergers and acquisitions or other partnering transactions. The team has been directly involved in financings of over $1 billion as well as mergers and acquisitions transactions valued at more than $2 billion. In the role immediately preceding the co-founding of Bloom Burton, Jolyon served as the Head of Healthcare & Biotechnology Investment Banking at an independent investment dealer. Jolyon started his career in roles that helped internationally focused growth companies, both at Export Development Canada and Global Affairs Canada.

    Mr. Burton serves as a Director of Grey Wolf Animal Health. He is a graduate of the University of Waterloo with an Honours Bachelor of Arts in Applied Studies, with a Major in Economics and Specializations in Finance and International Trade and received the Department of Economics award for academic achievement among his graduating class.

  • Daniel Chicoine - Director

    Mr. Chicoine is currently the Executive Chairman of Crescita Therapeutics Inc. (TSX:CTX ), where he oversees the investor relations function, and advises management on certain strategic business development projects from time to time. From March 1, 2016 until April 2, 2018, Mr. Chicoine served as Crescita’s Chairman and Interim Chief Executive Officer, at which time he was succeeded by Mr. Verreault. Mr. Chicoine served as Nuvo Research’s Chairman and Co-CEO and was actively involved in its day-to-day operations from 2004 to 2016 when Crescita became a reporting issuer following the reorganization of Nuvo Research into two separate publicly traded entities, Crescita and Nuvo Pharmaceuticals Inc. Prior to 2004, Mr. Chicoine held various senior executive positions at the Magna International group of companies, including President and Chief Executive Officer and Chief Financial Officer, and was the President of PowerCart Systems Inc., a Markham-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability. Mr. Chicoine is a graduate of the University of Toronto in commerce and is a Chartered Professional Accountant.

  • Sasha Cucuz - Director

    Mr. Cucuz is the Chief Executive Officer of Greybrook Securities, Inc. since 2005, where he directs Greybrook’s capital markets activities across the firm’s focus areas in real estate and healthcare. Operationally, Mr. Cucuz co-manages Greybrook Realty Partners’ business across both its Asset Management and Capital Markets verticals. Mr. Cucuz also serves as the Co-chair of Greybrook’s Advisory Committee for all active limited partnerships which include more than 50 real estate developments with an estimated completion value of approximately $14 billion, and the Co-chair of Greybrook’s investment committee. As the former CEO of Greybrook Health, Mr. Cucuz played a critical role in the launch of Greenbrook TMS and Greybrook’s prior portfolio acquisitions of MacuHealth and Bruder Health Care. He currently serves on the board of Greenbrook TMS, as well as on the boards of a number of Greybrook affiliated companies and the Blu Genes Foundation. After receiving a Bachelor of Arts in Economics from York University in 2000, Sasha went on to play professional hockey for three seasons. Mr. Cucuz began his career at TD Securities and CIBC before founding Greybrook Capital with his partners.

  • Dan Legault - Director

    Mr. Legault is the CEO of Antibe Therapeutics (TSXV:ATE) since 2009. Trained as a corporate lawyer and as an air force rescue pilot, Mr. Legault’s career has evolved to focus on high-growth, mostly technology-based companies. His CEO-level experience includes organizations specializing in data analytics, IT and consumer marketing. Mr. Legault has served on the boards of directors of International Save the Children and of Green Shield Canada, a leading health benefits administrator. Mr. Legault continues to serve as a board member and advisor to several companies and not-for-profit organizations. Mr. Legault is a member of the Law Society of Upper Canada and the New York State Bar.

  • Grishanth Ram - Director

    Mr. Ram is a finance executive with over 10 years of experience working in the healthcare industry. Between 2018 and 2019, Mr. Ram served as Chief Executive Officer and Executive Director of NeuPath, and has served on the board of directors of NeuPath since February 2018. Mr. Ram acted as the COO of InMedic Creative Medicine from 2011 to December 2019, prior to and following its acquisition by NeuPath in 2018. Mr. Ram holds a Bachelor of Science, Finance from DePaul University.

  • Joseph Walewicz - Director

    Mr. Joseph Walewicz was Executive Vice President, Business and Corporate Development of Clementia Pharmaceuticals, a NASDAQ-listed company, from 2017 to 2019 prior to Clementia’s acquisition by Ipsen Pharmaceuticals for US$1 billion in April of 2019. Mr. Walewicz has spent 25 years in biopharma, serving on the board and at the executive level of multiple publicly traded biopharma companies including Clementia Pharmaceuticals, MethylGene (now Mirati Therapeutics Inc.), Warnex Inc. and Paladin Labs, and as a top ranked equities analyst for major banks including CIBC, BMO, Lehman Brothers where he covered publicly traded North American biotechnology, pharmaceuticals, medtech and healthcare services companies. Mr. Walewicz holds a Master of Business Administration, Finance (McGill), as well as a Bachelor of Science, Biochemistry, and a Bachelor of Arts, Economics from Queen’s University. Mr. Walewicz is also a CFA (Chartered Financial Analyst) charterholder and a member of the Licensing Executives Society (LES).

Chronic Pain impacts 1 in 4 adults in Canada & 1 in 5 adults in the US.

Costs up to $635B annually in the US & $43B in Canada • Leading cause of disability worldwide